RBC Capital Maintains Outperform on Teladoc Health, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge maintains an Outperform rating on Teladoc Health and raises the price target from $9 to $10.
October 09, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on Teladoc Health and increased the price target from $9 to $10, indicating positive sentiment and potential for stock appreciation.
The increase in price target from $9 to $10 by RBC Capital suggests a positive outlook for Teladoc Health. The Outperform rating indicates that the analyst expects the stock to perform better than the market average, which could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100